PMID- 25204503
OWN - NLM
STAT- MEDLINE
DCOM- 20150225
LR  - 20181202
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 452
IP  - 3
DP  - 2014 Sep 26
TI  - Inhibition of DNA methylation enhances HLA-G expression in human mesenchymal stem 
      cells.
PG  - 753-9
LID - S0006-291X(14)01596-4 [pii]
LID - 10.1016/j.bbrc.2014.08.152 [doi]
AB  - Mesenchymal stem cells (MSCs) are immunosuppressive multipotent cells under 
      investigation for potential therapeutic applications in regenerative medicine and 
      prevention of graft-versus-host disease. Human leukocyte antigen (HLA)-G 
      contributes to the immunomodulatory properties of MSCs. HLA-G expression in MSCs 
      is very low and diminishes during in vitro expansion. Epigenetic regulation 
      activates HLA-G expression in some cancer cell lines but not in MSCs. In the 
      present study, adipose- and bone marrow-derived MSCs were exposed to the DNA 
      demethylating agent 5-aza-2-deoxycytidine (5-aza-dC) and histone deacetylase 
      inhibitor valproic acid (VPA) and HLA-G mRNA levels assessed using 
      semi-quantitative reverse-transcription PCR. Exposure to 5-aza-dC resulted in 
      HLA-G1 and -G3 upregulation in both early and late passage MSCs. VPA treatment 
      did not induce HLA-G expression in both bone marrow and adipose derived MSCs. Our 
      results provide the first evidence that HLA-G3 could be expressed in MSCs and 
      that methylation-mediated repression is partly responsible for the observed low 
      levels of HLA-G expression in MSCs. Our findings provide insight that treatment 
      of MSCs with specific epigenetic regulatory modulators may improve their 
      immunoregulatory capability for therapeutic applications.
CI  - Copyright (c) 2014 Elsevier Inc. All rights reserved.
FAU - Teklemariam, Takele
AU  - Teklemariam T
AD  - Escape Therapeutics, Inc., San Jose, CA, United States.
FAU - Purandare, Bhamini
AU  - Purandare B
AD  - San Jose State University, San Jose, CA, United States.
FAU - Zhao, Longmei
AU  - Zhao L
AD  - Escape Therapeutics, Inc., San Jose, CA, United States.
FAU - Hantash, Basil M
AU  - Hantash BM
AD  - Escape Therapeutics, Inc., San Jose, CA, United States. Electronic address: 
      basil@escapetherapeutics.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140906
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (HLA-G Antigens)
RN  - 0 (RNA, Messenger)
RN  - 614OI1Z5WI (Valproic Acid)
RN  - 776B62CQ27 (Decitabine)
RN  - M801H13NRU (Azacitidine)
SB  - IM
MH  - Adipose Tissue/cytology/drug effects/metabolism
MH  - Azacitidine/analogs & derivatives/pharmacology
MH  - Bone Marrow Cells/cytology/drug effects/metabolism
MH  - DNA Methylation/drug effects
MH  - Decitabine
MH  - *Epigenesis, Genetic
MH  - HLA-G Antigens/*genetics/metabolism
MH  - Humans
MH  - Mesenchymal Stem Cells/cytology/*drug effects/metabolism
MH  - Primary Cell Culture
MH  - RNA, Messenger/*genetics/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Signal Transduction
MH  - Valproic Acid/pharmacology
OTO - NOTNLM
OT  - 5-aza-2-deoxycytidine
OT  - Epigenetic regulation
OT  - HLA-G
OT  - Immunomodulation
OT  - Mesenchymal stem cells
OT  - Valproic acid
EDAT- 2014/09/11 06:00
MHDA- 2015/02/26 06:00
CRDT- 2014/09/11 06:00
PHST- 2014/08/26 00:00 [received]
PHST- 2014/08/28 00:00 [accepted]
PHST- 2014/09/11 06:00 [entrez]
PHST- 2014/09/11 06:00 [pubmed]
PHST- 2015/02/26 06:00 [medline]
AID - S0006-291X(14)01596-4 [pii]
AID - 10.1016/j.bbrc.2014.08.152 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2014 Sep 26;452(3):753-9. doi: 
      10.1016/j.bbrc.2014.08.152. Epub 2014 Sep 6.